Search

Statins are 3-hydroxy -3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors that reduce plasma cholesterol level by reducing cholesterol biosynthesis and inducing changes in low-density lipoprotein receptor expression. It is widely used in the treatment of hyperlipidemia and the prevention of cardiovascular and cerebrovascular diseases. In addition, statins may have potential anticancer effects by blocking cell cycle progression, inducing apoptosis, inhibiting angiogenesis, and inhibiting tumor growth and metastasis. Ovarian cancer has a poor prognosis and causes severe economic and psychological burden to patients. Statins exert anti-tumor effects and improve the chemoresistance of ovarian cancer by inhibiting mevalonic acid (MVA) pathway, promoting ferroptosis regulating autophagy and tumor microenvironment (TME). Studies have shown that statins, to some extent, can inhibit ovarian cancer cell proliferation, reduce the risk of ovarian cancer, improve the prognosis, synergize and enhance the anti-tumor effects of chemotherapy drugs, and reduce the recurrence rate. This article reviews the research progress of statins in the prevention and treatment of ovarian cancer, in order to provide help for future clinical practice. [ABSTRACT FROM AUTHOR]

Copyright of Journal of International Reproductive Health/Family Planning is the property of Editorial Board of the Journal of International Reproductive Health/Family Planning and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)